“Evolving Treatment Landscape of EGFR Mutant NSCLC” | Dr. Vamsidhar Velcheti

Vamsidhar Velcheti, MD MBA FACP FCCP
Professor of Medicine
Co- Director of Cancer Cell Biology
Program Director of Thoracic Medicine Oncology
Service Line Chief of Thoracic Oncology

With over a decade of experience in medical oncology and drug development, Dr. Velcheti is a Professor of Medicine and a Director of Thoracic Oncology Program at New York University. He leads a multidisciplinary team of researchers, clinicians, and educators who are dedicated to advancing the science and developing novel approaches to cancer treatment. He has a dual degree in medicine and business administration, and has advanced training in drug and medical device development and operational and change leadership. Dr. Velcheti has multiple publications, patents, and awards in the field of cancer research, and has extensive experience in conducting clinical trials, developing novel therapies, and collaborating with industry partners. He is passionate about teaching and mentoring the next generation of oncologists and innovators, and strives to create a culture of excellence, diversity, and collaboration in the program.

CLICK HERE to View Recording

Dr. Velcheti’s Objectives:

At the conclusion of this activity, participants will be able to:

•  Analyze management of EGFR mutant lung cancer
•  Examine new drugs in clinical development for the management of EGFR mutant lung cancer

Faculty Disclosure:

Dr. Velcheti has indicated the following relevant financial relationships with commercial interests:

Commercial Interest/Organization      Financial Relationship

MS , Merck, Roche                                          Advisor

Astrazenca, GSK                                              Advisor

Taiho Oncology, Takeda                                Advisor

Novocure, Regeneron                                     Consultant

Bayer, Novartis                                                Consultant

Picture Health, Amgen                                  Consultant

Planning Committee Disclosure

Dr. Lekakis has indicated that he has no relevant financial relationships with commercial interests.

Target Audience

Faculty, Primary Care Physicians, APRNs, PharmD

Accreditation

The University of Miami Leonard M. Miller School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The University of Miami Leonard M. Miller School of Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.